SR12813

• CAT Number: I001064
• CAS Number: 126411-39-0
• Molecular Formula: C24H42O7P2
• Molecular Weight: 504.5
• Purity: ≥95%
• Target: Pregnane X Receptors
• Solubility: 10 mM in DMSO
• Storage: Room Temperature
• IUPAC Name: 4-[2,2-bis(diethoxyphosphoryl)ethenyl]-2,6-ditert-butylphenol
• InChI: InChI=1S/C24H42O7P2/c1-11-28-32(26,29-12-2)21(33(27,30-13-3)31-14-4)17-18-15-19(23(5,6)7)22(25)20(16-18)24(8,9)10/h15-17,25H,11-14H2,1-10H3
• InChIKey: YQLJDECYQDRSBI-UHFFFAOYSA-N
• SMILES: CCOP(=O)(C(=CC1=CC(=C(C(=C1)C(C)(C)C)O)C(C)(C)C)P(=O)(OCC)OCC)OCC

SR12813 (Cat No.: I001064) is an exceptionally potent activator of the human and rabbit Pregnane X receptor (PXR), with EC50 values of 200 nM and 700 nM, respectively. Interestingly, its activation of PXR in rats and mice is relatively weak. SR12813 has demonstrated the ability to reduce cholesterol levels in various animals, including rats, dogs, and primates. Its unique receptor activation profile and lipid-lowering properties make it valuable in research related to cholesterol metabolism and potential therapeutic applications. For additional information or inquiries about SR12813, please feel free to contact us.

Reference

[1]. Berkhout T, et al. The novel cholesterol-lowering drug SR-12813 inhibits cholesterol synthesis via an increased degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Biol Chem. 1996 Jun 14;271(24):14376-82.
[2]. Jiang W, et al. Forward genetic screening for regulators involved in cholesterol synthesis using validation-based insertional mutagenesis. PLoS One. 2014 Nov 26;9(11):e112632.